Differentiating Surgical from Non-Surgical Lesions using Perfusion MR Imaging and Proton MR Spectroscopic Imaging

Abstract

Advanced MRI techniques, such as MR spectroscopy, diffusion and perfusion MR imaging can give important in vivo physiological and metabolic information, complementing morphologic findings from conventional MRI in the clinical setting. Combining perfusion MRI and MR spectroscopy can help in patients with brain masses in who the pre-operative differential diagnosis is unclear. This review demonstrates the use of dynamic, susceptibility weighted, contrast-enhanced MR imaging (DSC MRI) and magnetic resonance spectroscopic imaging (MRSI) to distinguish surgical from non-surgical lesions in the brain. There is overlap in the MRI appearance of many enhancing and ring-enhancing lesions such as gliomas, metastases, inflammatory lesions, demyelinating lesions, subacute ischemia, abscess and some AIDS related lesions. We review examples of histopathologically confirmed high-grade glioma, a middle cerebral artery territory infarct, a tumefactive demyelinating lesion and a metastasis for which conventional MR imaging (MRI) was non-specific and potentially misleading and demonstrate how DSC MRI and MRSI features were used to increase the specificity of neurodiagnosis. At several institutions, many patients routinely undergo MRI as well as MRSI and DSC MRI. Cerebral blood flow (CBF), mean transit time (MTT), and relative cerebral blood volume (rCBV) measurements are obtained from regions of maximal perfusion as determined from perfusion color overlay maps. Metabolite levels and ratios are determined for Choline (Cho), N-Acetyl Aspartate (NAA), Lactate and Lipids (LL). Metabolite levels are obtained by measuring the peak heights of each metabolite and the ratios are obtained from these measurements for Cho/Cr, Cho/NAA and NAA/Cr. Neurosurgical intervention carries substantial morbidity, mortality, financial and potential emotional cost to the patient and family. Making a pre-operative diagnosis allows the neurosurgeon to be confident in the choice of treatment plan for the patient and allays considerable patient anxiety. The utility of combining clinical findings with multi-parametric information from perfusion and spectroscopic MR imaging in differentiating surgical lesions from those which do not require surgical intervention is discussed.

Keywords

Perfusion MR Imaging Proton MR Spectroscopy (1H-MRS)Tumefactive demyelinating lesion High grade glioma Cerebral infarct

References

Law

Yang

Wang

Glioma Grading: Sensitivity, Specificity, and Predictive Values of Perfusion MR Imaging and Proton MR Spectroscopic Imaging Compared with Conventional MR Imaging. AJNR Am. J. Neuroradiol. 24, 1989–1998 (2003).

Alger

J. R.

Frank

J. A.

Bizzi

Metabolism of Human Gliomas: Assessment with H-1 MR Spectroscopy and F-18 Fluorodeoxyglucose PET. Radiology 177, 633–641 (1990).

Castillo

Proton MR Spectroscopy in Neoplastic and Non-Neoplastic Brain Disorders. MRI Clinics of North America 6, 1–19 (1998).

Castillo

and Kwock

Clinical Applications of Pro-ton Magnetic Resonance Spectroscopy in the Evaluation of Common Intracranial Tumors. Top Magn. Reson. Imaging 10, 104–113 (1999).

Kwock

Smith

J. K.

Castillo

Clinical Applications of Proton MR Spectroscopy in Oncology. Technol Cancer Res Treat 1, 17–28 (2002).

Negendank

W. G.

Sauter

Brown

T. R.

Proton Magnetic Resonance Spectroscopy in Patients with Glial Tumors: A Multicenter Study. J. Neurosurg. 84, 449–458 (1996).

Law

Cha

Knopp

E. A.

Johnson

Arnett

, and Litt

A. W.

High-Grade Gliomas and Solitary Metastases: Differentiation by Using Perfusion and Proton Spectroscopic MR Imaging. Radiology 222, 715–721 (2002).

Ricci

P. E.

Pitt

Keller

P. J.

Coons

S. W.

, and Heiserman

J. E.

Effect of Voxel Position on Single-voxel MR Spectroscopy Findings. AJNR Am. J. Neuroradiol. 21, 367–374. (2000).

Saunders

D. E.

MR Spectroscopy in Stroke. Br. Med. Bull. 56, 334–345 (2000).

10.

Cha

Knopp

E. A.

Johnson

Wetzel

S. G.

Litt

A. W.

, and Zagzag

Intracranial Mass Lesions: Dynamic Contrast-enhanced Susceptibility-weighted Echo-planar Perfusion MR Imaging. Radiology 223, 11–29 (2002).

11.

Cha

Perfusion MR Imaging: Basic Principles and Clinical Applications. Magn. Reson. Imaging Clin. N. Am. 11, 403–413 (2003).

12.

Knopp

E. A.

Cha

Johnson

Glial Neoplasms: Dynamic Contrast-enhanced T2*-weighted MR Imaging. Radiology 211, 791–798 (1999).

13.

Law

Yang

Babb

J. S.

Comparison of Cerebral Blood volume and Vascular Permeability from Dynamic Susceptibility Contrast-enhanced Perfusion MR Imaging with Glioma Grade. AJNR Am. J. Neuroradiol. 25, 746–755 (2004).

14.

Warmuth

Gunther

, and Zimmer

Quantification of Blood Flow in Brain Tumors: Comparison of Arterial Spin Labeling and Dynamic Susceptibility-weighted Contrast-enhanced MR Imaging. Radiology 228, 523–532 (2003).

15.

Albayrak

Zhao

Siesjo

B. K.

, and Smith

M. L.

Effect of Transient Focal Ischemia on Blood Brain Barrier Permeability in the Rat: Correlation to Cell Injury. Acta. Neuropathol. 94, 158–163 (1997).

16.

Harris

N. G.

Gauden

Fraser

P. A.

Williams

S. R.

, and Parker

G. J.

MRI Measurement of Blood-brain Barrier Permeability Following Spontaneous Reperfusion in the Starch Microsphere Model of Ischemia. Magn. Reson. Imaging 20, 221–230 (2002).

17.

Plutaa

Lossinskyb

A. S.

Winiewskib

H. M.

, and Mossakowski

M. J.

Early blood-brain Barrier Changes in the Rat Following Transient Complete Cerebral Ischemia Induced by Cardiac Arrest. Brain Research 633, 41–52 (1994).

18.

Sorensen

A. G.

Buonanno

F. S.

Gonzalez

R. G.

Hyperacute Stroke: Evaluation with Combined Multisection Diffusion-weighted and Hemodynamically Weighted Echo-planar MR Imaging. Radiology 199, 391–401 (1996).

19.

Moller-Hartmann

Herminghaus

Krings

Clinical Application of Proton Magnetic Resonance Spectroscopy in the Diagnosis of Intracranial Mass Lesions. Neuroradiology 44, 371–381 (2002).

20.

Fulham

M. J.

Bizzi

Dietz

M. J.

Mapping of Brain Tumor Metabolites with Proton MR Spectroscopic Imaging: Clinical Relevance. Radiology 185, 675–686 (1992).

21.

Tzika

A. A.

Zarifi

M. K.

Goumnerova

Neuroimaging in Pediatric Brain Tumors: Gd-DTPA-enhanced, Hemodynamic, and Diffusion MR Imaging Compared with MR Spectroscopic Imaging. AJNR Am. J. Neuroradiol. 23, 322–333. (2002).

22.

Yang

Korogi

Sugahara

Cerebral Gliomas: Prospective Comparison of Multivoxel 2D Chemical-shift Imaging Proton MR Spectroscopy, Echoplanar Perfusion, and Diffusion-weighted MRI. Neuroradiology 44, 656–666 (2002).

23.

Castillo

and Kwock

Proton MR Spectroscopy of Common Brain Tumors. Neuroimaging Clin. N. Am. 8, 733–752 (1998).

24.

Kwock

L. A.

Tuning in on Tumor Activity with Proton MR Spectroscopy. Ajnr: American Journal of Neuroradiology 22, 807–808 (2001).

25.

Fountas

K. N.

Kapsalaki

E. Z.

Gotsis

S. D.

In Vivo Proton Magnetic Resonance Spectroscopy of Brain Tumors. Stereotact Funct Neurosurg 74, 83–94 (2000).

26.

Shimizu

Kumabe

Shirane

, and Yoshimoto

Correlation Between Choline Level Measured by Proton MR Spectroscopy and Ki-67 labeling index in Gliomas. AJNR Am. J. Neuroradiol. 21, 659–665 (2000).

27.

Shimizu

Kumabe

Tominaga

Noninvasive Evaluation of Malignancy of Brain Tumors with Proton MR Spectroscopy. AJNR Am. J. Neuroradiol. 17, 737–747 (1996).

28.

Sorensen

A. G.

Copen

W. A.

Ostergaard

Hyperacute Stroke: Simultaneous Measurement of Relative Cerebral Blod volume, Relalative Cerebral Blood Flow, and Mean Transit Time. Radiology 210 (1999).

29.

Sorensen

A. G.

and Reimer

Cerbral MR Perfusion Imaging: Principles and Current Applications. New York: Thieme (2000).

30.

Karonen

Liu

Vanninen

Combined Perfusion-and Diffusion-weighted MR Imaging in Acute Ischemic Stroke during the 1st Week: A Longitudinal Study. Radiology 217, 886–894 (2000).

31.

Vajkoczy

and Menger

M. D.

Vascular Microenvironment in Gliomas. J. Neurooncol. 50, 99–108 (2000).

32.

Karonen

Vanninen

R. L.

Liu

Combined Diffusion and Perfusion MRI with Correlation to Single-photon Emission CT in Acute Ischemic Stroke: Ischemic Penumbra Predicts Infarct Growth. Stroke 30, 1583–1590 (1999).

33.

Hatazawa

Shimosegawa

Toyoshima

Cerebral Blood volume in Acute Brain Infarction: A Combined Study with Dynamic Susceptibility Contrast MRI and 99 mTc-HMPAO-SPECT. Stroke 30, 800–806 (1999).

34.

Crosby

Simonson

Fisher

Echo-planar MR Imaging: Correlation of Intracranial Perfusion-sensitive Imaging with Cerebral Angiography. Society of Magnetic Resonance 277 (1994).

35.

Cha

Pierce

Knopp

E. A.

Dynamic Contrast-enhanced T2*-weighted MR Imaging of Tumefactive Demyelinating Lesions. AJNR Am. J. Neuroradiol. 22, 1109–1116 (2001).

36.

Saindane

A. M.

Cha

Law

Xue

Knopp

E. A.

, and Zagzag

Proton MR Spectroscopy of Tumefactive Demyelinating Lesions. AJNR Am. J. Neuroradiol. 23, 1378–1386 (2002).

37.

Law

Meltzer

D. E.

, and Cha

Spectroscopic Magnetic Resonance Imaging of a Tumefactive Demyelinating Lesion. Neuroradiology 44, 986–989 (2002).

38.

Arnold

D. L.

Matthews

P. M.

Francis

G. S.

O'Connor

, and Antel

J. P.

Proton Magnetic Resonance Spectroscopic Imaging for Metabolic Characterization of Demyelinating Plaques. Ann. Neurol. 31, 235–241 (1992).

39.

Bitsch

Bruhn

Vougioukas

Inflammatory CNS Demyelination: Histopathologic Correlation with In Vivo Quantitative Proton MR Spectroscopy. AJNR Am. J. Neuroradiol. 20, 1619–1627 (1999).

40.

Davie

C. A.

Hawkins

C. P.

Barker

G. J.

Serial Proton Magnetic Resonance Spectroscopy in Acute Multiple Sclerosis Lesions. Brain 117 (Pt 1), 49–58 (1994).

41.

Silva

H. C.

Callegaro

Marchiori

P. E.

Scaff

, and Tsanaclis

A. M.

Magnetic Resonance Imaging in Five Patients with a Tumefactive Demyelinating Lesion in the Central Nervous System. Arq. Neuropsiquiatr. 57, 921–926 (1999).

42.

Kwock

Castillo

, and Smith

J. K.

Comparison of Proton MR Spectral Patterns of Glioblastoma Multiforme (GBM) Versus Metastatic Brain Tumors. In Proceedings of the Annual Meeting of the American Society of Neuroradiology, pp. 58. San Diego, CA (1999).

43.

Preul

M. C.

Caramanos

Collins

D. L.

Accurate, Noninvasive Diagnosis of Human Brain Tumors by Using Proton Magnetic Resonance Spectroscopy. Nat. Med. 2, 323–325 (1996).

44.

Ishimaru

Morikawa

Iwanaga

Kaminogo

Ochi

, and Hayashi

Differentiation Between High-grade Glioma and Metastatic Brain Tumor Using Single-voxel Proton MR Spectroscopy. Eur. Radiol. 11, 1784–1791 (2001).

45.

Burger

P. C.

Classification, Grading, and Patterns of Spread of Malignant Gliomas. In Neurosurgical topics: malignant cerebral glioma , pp. 3–17. Ed. Apuzzo . In America Association of Neurological Surgeons. Park Ridge, Ill (1990).

46.

Burger

P. C.

Vogel

F. S.

Green

S. B.

, and Strike

T. A.

Glioblastoma Multiforme and Anaplastic Astrocytoma: Pathologic Criteria and Prognostic Implications. Cancer 56, 1106–1111 (1985).

47.

Bhujwalla

Z. M.

Artemov

Natarajan

Solaiyappan

Kollars

, and Kristjansen

P. E. G.

Reduction of Vascular and Permeable Regions in Solid Tumors Detected by Macromolecular Contrast Magnetic Resonance Imaging after Treatment with Antiangiogenic Agent TNP-470. Clin. Cancer. Res. 9, 355–362 (2003).

48.

Cha

Knopp

E. A.

Johnson

Dynamic, Contrast-enhanced T2*-weighted MR Imaging of Recurrent Malignant Gliomas Treated with Thalidomide and Carboplatin. American Journal of Neuroradiology 21, 881–890 (2000).